1. Home
  2. NEWP vs RIGL Comparison

NEWP vs RIGL Comparison

Compare NEWP & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEWP
  • RIGL
  • Stock Information
  • Founded
  • NEWP 1972
  • RIGL 1996
  • Country
  • NEWP Canada
  • RIGL United States
  • Employees
  • NEWP N/A
  • RIGL N/A
  • Industry
  • NEWP
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEWP
  • RIGL Health Care
  • Exchange
  • NEWP Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • NEWP 363.2M
  • RIGL 335.5M
  • IPO Year
  • NEWP N/A
  • RIGL 2000
  • Fundamental
  • Price
  • NEWP $2.17
  • RIGL $37.96
  • Analyst Decision
  • NEWP
  • RIGL Buy
  • Analyst Count
  • NEWP 0
  • RIGL 5
  • Target Price
  • NEWP N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • NEWP 434.0K
  • RIGL 761.5K
  • Earning Date
  • NEWP 11-12-2025
  • RIGL 11-06-2025
  • Dividend Yield
  • NEWP N/A
  • RIGL N/A
  • EPS Growth
  • NEWP N/A
  • RIGL N/A
  • EPS
  • NEWP N/A
  • RIGL 5.43
  • Revenue
  • NEWP N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • NEWP N/A
  • RIGL $59.93
  • Revenue Next Year
  • NEWP N/A
  • RIGL N/A
  • P/E Ratio
  • NEWP N/A
  • RIGL $6.99
  • Revenue Growth
  • NEWP N/A
  • RIGL 105.62
  • 52 Week Low
  • NEWP $0.93
  • RIGL $12.76
  • 52 Week High
  • NEWP $2.17
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • NEWP 69.94
  • RIGL 56.17
  • Support Level
  • NEWP $1.88
  • RIGL $35.56
  • Resistance Level
  • NEWP $2.15
  • RIGL $42.65
  • Average True Range (ATR)
  • NEWP 0.12
  • RIGL 2.19
  • MACD
  • NEWP 0.03
  • RIGL -1.00
  • Stochastic Oscillator
  • NEWP 99.02
  • RIGL 32.70

About NEWP New Pacific Metals Corp.

New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: